Document Detail


TNK-tPA (tenecteplase).
MedLine Citation:
PMID:  20635756     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Management of acute myocardial infarction (AMI) has undergone seismic changes in the last two decades, primarily with the global availability of thrombolytic agents and with the burgeoning use of Primary PCI. Application of these two modalities has dramatically reduced both the mortality and morbidity from AMI. Advances in thrombolytic therapy have been noteworthy in three areas: firstly, in genetically engineering superior third-generation lytic agents: secondly, in developing protocols of appropriate use, and thirdly, creating unambiguous guidelines for admninistration of thrombolytics, of utilizing Primary PCI, or hybrid strategies. Our submitted review on thrombolytic therapy builds on this scientific progress. It provides a pertinent historical perspective that elucidates discovery of lytic agents and the vast array of biogenetic inventions that lead to the development of the novel agent, tenecteplase. The review manuscript also provides a comprehensive compendium of the numerous clinical trials that have been methodically presented in easy-to-read tables. We have additionally designed these tables to facilitate comparison of different lytic agents and for critical analysis of the individual clinical trials. Finally, to make this review most relevant for the IHJ, a section has been devoted to the use of thrombolytic therapy in India. Unique attributes of tenecteplase have been discussed and the benefits of using it to treat Indian patients have been highlighted.
Authors:
Sameer Mehta; Estefanía Oliveros; Salomon Cohen; Esther Falcão; Ana I Flores
Related Documents :
1452916 - Invasive versus conservative strategy after thrombolytic therapy for acute myocardial i...
8711486 - Thrombolytic therapy in acute myocardial infarction.
15931696 - Correlation between cortisol levels and myocardial infarction mortality among intensive...
2183696 - Thrombolytic therapy in myocardial infarction.
18498956 - Early and late benefits of prasugrel in patients with acute coronary syndromes undergoi...
1452916 - Invasive versus conservative strategy after thrombolytic therapy for acute myocardial i...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Indian heart journal     Volume:  61     ISSN:  0019-4832     ISO Abbreviation:  Indian Heart J     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2010-07-19     Completed Date:  2010-08-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374675     Medline TA:  Indian Heart J     Country:  India    
Other Details:
Languages:  eng     Pagination:  422-32     Citation Subset:  IM    
Affiliation:
Miller School of Medicine, University of Miami & Mercy Medical Center, Miami, Florida, USA. mehtas@bellsouth.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary
Fibrinolytic Agents / administration & dosage,  therapeutic use*
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Myocardial Infarction / drug therapy*,  therapy
Randomized Controlled Trials as Topic
Tissue Plasminogen Activator / administration & dosage,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 0/tenecteplase; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Echocardiographic assessment of right heart hemodynamics.
Next Document:  Pre-hospital thrombolysis.